$12.84
Today
as of Jul 22, 16:51 ET
Last 30 days
Recent Press Releases & News
Lyell Immunopharma Files for Secondary Offering of Common Shares
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Overview
52-week range
$8.46
$45
12% of range
Avg surprise (last 3)
+29.9%
Avg reaction (last 2)
-1.5%
50% positive
Latest IV / EM
170%
EM ±38.9% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-1.10 | $-2.78 | +60.4% | -511.1% | +1.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-2.13 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-2.89 | $-3.80 | +23.9% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.18 | $-0.19 | +5.3% | — | -4.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-3.48 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-3.59 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.24 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.20 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.26 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$1.88 | -$2.89 | +35.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2,000 | — | $15,000 | $8,000 | $7,000 | — | $34,000 | $13,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-44M | — | $-37M | $-47M | $-57M | — | $-51M | $-52M |
| Net income | $-24M | — | $-39M | $-43M | $-52M | — | $-45M | $-46M |
| EPS (diluted) | $-1.10 | — | $-2.13 | $-2.89 | $-3.54 | — | $-3.48 | $-3.59 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $91M | $60M | $124M | $99M | $120M | $106M | $100M | $133M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $267M | $261M | $328M | $282M | $309M | $380M | $450M | $500M |
| Total assets | $351M | $340M | $408M | $385M | $430M | $491M | $619M | $654M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $77M | $92M | $79M | $87M | $93M | $108M | $89M | $88M |
| Total equity | $274M | $248M | $329M | $299M | $337M | $383M | $531M | $567M |